- Favorable Safety Profile Across All Tested Doses Supports Initiation of a Phase 2 Trial in Patients with Spinal Muscular
Atrophy (SMA)
- Pharmacodynamic Results Demonstrate Robust and Sustained Target Engagement of Latent Myostatin
- Phase 2 Trial Initiation Expected by the End of 1Q19 with Interim Safety and Efficacy Analysis Following Six Months of
Treatment Expected in 1H20
- Company to Host Conference Call and Webcast on February 26, 2019 at 8:00 a.m. ET
CAMBRIDGE, Mass., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company
focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced positive
interim results from the ongoing Phase 1 single- and multiple-ascending dose clinical trial of SRK-015 in healthy adult volunteers.
SRK-015, a highly specific inhibitor of myostatin activation, was observed to be well tolerated with no apparent safety
signals. By demonstrating robust and sustained target engagement in humans, pharmacologic effects on serum concentrations of
latent myostatin show initial proof-of-mechanism for this unique therapeutic approach. The favorable interim safety and
tolerability, pharmacodynamic (PD), and pharmacokinetic (PK) data support the advancement of SRK-015 to a Phase 2 proof-of-concept
clinical trial in patients with spinal muscular atrophy (SMA), evaluating a once every four-week dosing regimen.
“We are very excited with the progress to date in the Phase 1 trial of SRK-015 as we continue to work towards developing our
lead antibody candidate as a potential first muscle-directed therapy for the treatment of SMA,” said Yung Chyung, M.D., Chief
Medical Officer of Scholar Rock. “We look forward to initiating the Phase 2 proof-of-concept trial to evaluate SRK-015’s potential
to address the functional deficits that continue to represent a significant unmet need in SMA.”
Phase 1 Trial Design and Interim Results
Trial Design. The randomized, double-blind, placebo-controlled Phase 1 clinical trial was designed to evaluate
the safety and tolerability of intravenously administered SRK-015, assess the PK/PD profile, and inform dosing for the Phase 2
trial.
- Single-Ascending Dose (SAD): Enrolled 40 adult healthy volunteers, randomized 3:1 to receive a single dose
of SRK-015 or placebo, and evaluated doses of 1, 3, 10, 20 and 30 mg/kg.
- Multiple-Ascending Dose (MAD): Enrolled 26 adult healthy volunteers, randomized 3:1 to receive SRK-015 or
placebo every two weeks for a total of three doses (Day 0, 14 and 28). The MAD portion of the trial evaluated doses of 10, 20 and
30 mg/kg.
The interim analysis was conducted with data from all subjects in the completed SAD portion of the trial and available data for
all subjects in the MAD portion of the trial, including through Day 35 for the highest 30 mg/kg dose cohort and longer follow-up
for the 10 and 20 mg/kg dose cohorts. Follow-up in the MAD portion of the trial is ongoing and full clinical results from the
Phase 1 trial will be presented at a scientific conference this year.
Safety and Immunogenicity Data. SRK-015 was observed to be well tolerated with no dose-limiting toxicities
identified up to the highest evaluated dose of 30 mg/kg. There were no deaths, no discontinuations due to a treatment-related
adverse event (AE), no treatment-related serious AEs (SAE), and no hypersensitivity reactions. In the SAD portion of the
trial, AEs were observed in 30% (9/30) of SRK-015-treated subjects and 50% (5/10) of placebo-treated subjects. In the MAD
portion of the trial, AEs were observed in 30% (6/20) of SRK-015-treated subjects and 67% (4/6) of placebo-treated subjects.
A single SAE (gallstone-induced pancreatitis) was observed and assessed by the trial investigator as unrelated to SRK-015
treatment. Immunogenicity as evaluated by anti-drug antibody testing was negative for all subjects in the SAD portion of the
trial and data for subjects in the MAD portion of the trial are pending completion of the Phase 1 trial.
Biomarker/Pharmacodynamic Data. PD was evaluated through a proprietary, exploratory biomarker assay
developed by Scholar Rock that measures serum concentrations of latent myostatin. This assay was used previously to
demonstrate target engagement in preclinical studies in healthy animals and a mouse model of SMA. Following a single dose of
SRK-015 in this Phase 1 trial, levels of latent myostatin were markedly increased from baseline, confirming target engagement.
The levels of target engagement attained a plateau, suggesting that the target was saturated after a single dose of SRK-015
at 3 mg/kg or greater. Moreover, this plateau was sustained through Day 28 after a single dose at 10 mg/kg and through at
least Day 84 after a single dose at 20 mg/kg or 30 mg/kg, indicating durability of this effect. In contrast, no meaningful
change was observed in the latent myostatin biomarker concentrations in subjects who received placebo.
Pharmacokinetic Data. Based on data from the SAD, SRK-015 displayed a PK profile consistent with what is
generally observed for monoclonal antibodies. Drug exposure was dose-proportional and the serum half-life was 23-33 days across the
SRK-015 dose groups, supporting the investigation of a once every four-week dosing regimen in the Phase 2 trial.
“These interim Phase 1 data provide initial proof-of-mechanism for the pharmacologic potential of SRK-015, and more broadly,
Scholar Rock’s therapeutic approach of specifically targeting the latent forms of growth factors,” said Nagesh Mahanthappa, Ph.D,
President and CEO of Scholar Rock. “Through our discovery efforts, we have built a robust pipeline of highly specific growth
factor modulators across a diverse range of therapeutic areas and are eagerly working to advance these potential therapies to serve
patients with unmet medical needs.”
Phase 2 (TOPAZ) Trial Overview
Scholar Rock’s preclinical data and translational insights highlight the promising potential of myostatin as a drug target in
SMA, and positive interim results from the Phase 1 study demonstrate that SRK-015 may have the necessary pharmacologic profile to
modulate this pathway.
Scholar Rock plans to initiate a Phase 2 proof-of-concept clinical trial to assess the safety and efficacy of SRK-015 in
patients with Type 2 and Type 3 SMA by the end of the first quarter of 2019. The trial will include three cohorts, each
representing a distinct subpopulation of patients. A total of 50-60 patients are planned to be enrolled in the Phase 2 trial
and all patients will receive SRK-015 dosed once every four weeks (Q4W) either as a monotherapy or in conjunction with an approved
SMN upregulator therapy. The primary efficacy endpoints will measure motor function through clinically meaningful outcome
measures validated in SMA, such as the Hammersmith Functional Motor Scale Expanded (HFMSE) in non-ambulatory SMA and the Revised
Hammersmith Scale (RHS) in ambulatory SMA, over a 12-month treatment period. Scholar Rock plans to provide additional
details on the trial design at the time of initiating patient dosing in the second quarter of 2019.
An interim analysis assessing safety and efficacy is planned for each cohort of the Phase 2 trial, encompassing a subset of
patients with at least 6 months of treatment exposure. These interim results by cohort are expected in the first half of
2020. Top-line results for the full 12-month treatment period are expected starting in the fourth quarter of 2020 and through
the first quarter of 2021. In addition, analyses of preliminary PK and PD data are planned by the end of 2019.
Conference Call Information
Scholar Rock will host a conference call and webcast to review the interim Phase 1 results and the Phase 2 trial design on Tuesday,
February 26, 2019 at 8:00 am ET. The call may be accessed by phone by calling 1-866-809-6221 (U.S.) or 1-409-981-0877
(international) using the conference ID 1394467. The webcast may be accessed live by visiting the Investors & Media section
of the Scholar Rock website at http://investors.scholarrock.com. An archived replay of the webcast will be available on
the Company’s website for approximately 90 days following the call.
About SRK-015
SRK-015 is a selective inhibitor of the
activation of myostatin and is an investigational product candidate for the treatment of patients with spinal muscular atrophy
(SMA). Myostatin, a member of the TGF-beta superfamily of growth factors, is expressed primarily by skeletal muscle cells and
the absence of its gene is associated with an increase in muscle mass and strength in multiple animal species. Scholar
Rock believes the inhibition of the activation of myostatin with SRK-015 may promote a clinically meaningful increase in
muscle mass and strength. A Phase 1 clinical trial in healthy volunteers is ongoing and a Phase 2 trial is expected to
initiate by the end of the first quarter of 2019. The U.S. Food and Drug Administration (FDA) has granted Orphan Drug
Designation (ODD), and the European Commission (EC) has granted Orphan Medicinal Product Designation, to SRK-015 for the treatment
of SMA. The effectiveness and safety of SRK-015 have not been established and SRK-015 has not been approved by the
FDA or any other regulatory agency.
About SMA
Spinal muscular atrophy (SMA) is a rare, and often fatal, genetic disorder that typically manifests in young children. An estimated
30,000 to 35,000 patients are afflicted with SMA in the United States and Europe. It is characterized by the loss of motor neurons,
atrophy of the voluntary muscles of the limbs and trunk and progressive muscle weakness. The underlying pathology of SMA is caused
by insufficient production of the SMN (survival of motor neuron) protein, essential for the survival of motor neurons and is
encoded by two genes, SMN1 and SMN2. While there has been progress in the development of therapeutics that address the
underlying SMA genetic defect, there continues to be a high unmet need for therapeutics that directly address muscle atrophy.
About Scholar Rock
Scholar Rock is a clinical-stage
biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in
which signaling by protein growth factors plays a fundamental role. Scholar Rock is creating a pipeline of novel
product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including
neuromuscular disorders, cancer, fibrosis and anemia. Scholar Rock’s newly elucidated understanding of the molecular
mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and
development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. By
developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges
associated with inhibiting growth factors for therapeutic effect. Scholar Rock believes its focus on biologically validated
growth factors may facilitate a more efficient development path. For more information, please visit www.ScholarRock.com or follow Scholar Rock on Twitter (@ScholarRock) and LinkedIn (https://www.linkedin.com/company/scholar-rock/).
Scholar Rock® is a registered trademark of Scholar Rock, Inc.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of
1995, including, but not limited to, statements regarding Scholar Rock’s future expectations, plans and prospects, including
without limitation, Scholar Rock’s expectations regarding the potential of SRK-015 as a therapy in SMA and the timeline for and
progress in developing SRK-015. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,”
“believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to
identify such forward-looking statements. All such forward-looking statements are based on management's current expectations of
future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and
adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include those risks
more fully discussed in the section entitled "Risk Factors" in Scholar Rock’s Quarterly Report on Form 10-Q for the quarter
ended September 30, 2018, as well as discussions of potential risks, uncertainties, and other important factors in Scholar
Rock’s subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent Scholar Rock’s
views only as of today and should not be relied upon as representing its views as of any subsequent date. All information in
this press release is as of the date of the release, and Scholar Rock undertakes no duty to update this information
unless required by law.
Scholar Rock Contact: Investors/Media Catherine Hu, 917-601-1649 chu@scholarrock.com Media Contact: The Yates Network Kathryn Morris, 914-204-6412 kathryn@theyatesnetwork.com
